uniQure (QURE) Total Non-Current Liabilities (2015 - 2026)
uniQure's (QURE) quarterly Total Non-Current Liabilities came in at $570.2 million in Q1 2026, up 6.49% year-on-year from $535.4 million in Q1 2025, and up 1.26% quarter-over-quarter from $563.1 million in Q4 2025.
uniQure (QURE) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $570.2 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 6.49% year-over-year to $570.2 million in Q1 2026; TTM through Mar 2026 was $570.2 million, a 6.49% increase from a year earlier, with the FY2025 full-year figure at $563.1 million, up 7.62% from the prior year.
- Total Non-Current Liabilities climbed to $570.2 million in Q1 2026 per QURE's latest filing, from $563.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $570.2 million in Q1 2026 and bottomed at $151.9 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $534.2 million (2023), against an average of $431.0 million.
- Across the five-year window, Total Non-Current Liabilities slipped 13.36% in 2022 and surged 268.55% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $153.0 million in 2022, then soared by 259.62% to $550.3 million in 2023, then fell by 4.93% to $523.2 million in 2024, then advanced by 7.62% to $563.1 million in 2025, then gained by 1.26% to $570.2 million in 2026.
- Per Business Quant, the three latest QURE Total Non-Current Liabilities figures stand at $570.2 million (Q1 2026), $563.1 million (Q4 2025), and $559.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | uniQure | 2.47 Bn | 2.47 Bn | 3.34 Mn | 570.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 570.17 Mn |
| Dec 31, 2025 | 563.09 Mn |
| Sep 30, 2025 | 559.00 Mn |
| Jun 30, 2025 | 547.96 Mn |
| Mar 31, 2025 | 535.41 Mn |
| Dec 31, 2024 | 523.24 Mn |
| Sep 30, 2024 | 518.71 Mn |
| Jun 30, 2024 | 553.27 Mn |
| Mar 31, 2024 | 559.82 Mn |
| Dec 31, 2023 | 550.34 Mn |
| Sep 30, 2023 | 534.16 Mn |
| Jun 30, 2023 | 521.09 Mn |
| Mar 31, 2023 | 151.90 Mn |
| Dec 31, 2022 | 153.04 Mn |
| Sep 30, 2022 | 153.09 Mn |
| Jun 30, 2022 | 166.46 Mn |
| Mar 31, 2022 | 166.45 Mn |
| Dec 31, 2021 | 176.64 Mn |
| Sep 30, 2021 | 141.95 Mn |
| Jun 30, 2021 | 104.56 Mn |